Systemic therapy for small cell lung cancer

Benjamin Levy, Ashish Saxena, Bryan J. Schneider

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Small cell lung cancer is an aggressive tumor characterized by genetic complexity, rapid doubling time, and early development of disseminated disease. Unfortunately, few chemotherapeutic advances have been made in the treatment of extensive-stage disease, and cisplatin/etoposide has remained the standard of care for more than 30 years. Other regimens with comparable efficacy include cisplatin/irinotecan and carboplatin/etoposide. Each of these combinations is associated with a different toxicity profile that must be considered when selecting an initial regimen. Several strategies, including maintenance chemotherapy, 3-drug combinations, alternating combination chemotherapy regimens, and high-dose chemotherapy, have consistently failed to demonstrate improvements in survival when compared with 4 to 6 cycles of platinum doublets. Several options are available for patients who experience progression during or relapse after induction therapy, although topotecan is the only FDA-approved agent for second-line treatment. Recently, scientific efforts have identified potentially actionable genetic alterations in small cell tumors that may lead to the development of effective, targeted therapies.

Original languageEnglish
Pages (from-to)780-787
Number of pages8
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume11
Issue number7
DOIs
StatePublished - 1 Jul 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Systemic therapy for small cell lung cancer'. Together they form a unique fingerprint.

Cite this